Ph. Eur. General Notices Chapter - New Structure and Content
The European Pharmacopoeia (Ph. Eur.) Commission adopted a revised version of Ph. Eur. chapter 1. General Notices to provide greater clarity for users.
New structure and content
The revised Ph. Eur. chapter 1 General Notices features new additions such as
- a section on monographs for medicinal products containing chemically defined APIs. This new section also provides information on related substances and impurities.
- a sub-section on “Demonstration of suitability of monographs”.
- a single section concerning monographs on herbal drugs, containing all paragraphs that were previously dispersed throughout the text.
- an explanation of the rounding rule, information on chiral substances and an example of equivalents (in the tests and assay sections).
-
a clarification of the scope of first and second identification series and of alternative identifications.
In addition, the wording and terminology have been further harmonized. For example,
- “medicinal product” is selected instead of “finished product” and “pharmaceutical preparation”.
- “shelf life” and “re-test period” will be used instead of “period of use” and “period of validity”.
The revised Ph. Eur. chapter 1 General Notices will be published in Ph. Eur. Supplement 10.7, available in October 2021 (implementation date: 1 April 2022).
More information can be found in the EDQM Newsroom: Adoption of the revised General Notices chapter.
Related GMP News
20.08.2025What is the FDA Post-Warning Letter Meeting?
20.08.2025European Pharmacopoeia: New Online-only Platform
20.08.2025Events in an Audit Trail and Determination of GMP-Relevant Data in the Audit Trail
20.08.2025The Importance of Knowledge Management in GMP
13.08.2025FDA assesses economic Benefits of investing in Quality Management
13.08.2025How to Deal with Audit Trails in Preconfigured Equipment?